Department of Neurology, Washington University School of Medicine, 660 S. Euclid Ave, Box 8111, St. Louis, MO, 63110, USA,
J Neurol. 2013 Dec;260(12):3115-21. doi: 10.1007/s00415-013-7123-8. Epub 2013 Oct 8.
We compared features of nerve enlargement in inherited and acquired demyelinating neuropathies using ultrasound. We measured median and ulnar nerve cross-sectional areas in proximal and distal regions in 128 children and adults with inherited [Charcot-Marie-Tooth-1 (CMT-1) (n = 35)] and acquired [chronic inflammatory demyelinating polyneuropathy (CIDP) (n = 55), Guillaine-Barre syndrome (GBS) (n = 21) and multifocal motor neuropathy (MMN) (n = 17)] demyelinating neuropathies. We classified nerve enlargement by degree and number of regions affected. We defined patterns of nerve enlargement as: none, no enlargement; mild, nerves enlarged but never more than twice normal; regional, nerves normal in at least one region and enlarged more than twice normal in at least one region; diffuse, nerves enlarged at all four regions with at least one region more than twice normal size. Nerve enlargement was commonly diffuse (89 %) and generally more than twice normal size in CMT-1, but not (p < 0.001) in acquired disorders which mostly had either no, mild or regional nerve enlargement [CIDP (64 %), GBS (95 %), and MMN (100 %)]. In CIDP, subjects treated within 3 months of disease onset had less nerve enlargement than those treated later. Ultrasound identified patterns of diffuse nerve enlargement can be used to screen patients suspected of having CMT-1. Normal, mildly, or regionally enlarged nerves in demyelinating polyneuropathy suggests an acquired etiology. Early treatment in CIDP may impede nerve enlargement.
我们使用超声比较了遗传性和获得性脱髓鞘神经病中神经增大的特征。我们测量了 128 名儿童和成人中正中神经和尺神经的近侧和远侧节段的横截面积,这些人患有遗传性(Charcot-Marie-Tooth-1 [CMT-1](n=35))和获得性(慢性炎症性脱髓鞘性多发性神经病[CIDP](n=55)、吉兰-巴雷综合征[GBS](n=21)和多灶性运动神经病[MMN](n=17))脱髓鞘神经病。我们按程度和受累区域数量对神经增大进行分类。我们将神经增大模式定义为:无,无增大;轻度,神经增大但从未超过正常的两倍;区域性,至少有一个区域的神经正常且至少有一个区域的神经增大超过正常的两倍;弥漫性,四个区域的神经均增大,至少有一个区域的神经比正常尺寸大两倍以上。神经增大通常是弥漫性的(89%),在 CMT-1 中通常超过正常尺寸的两倍,但在获得性疾病中并非如此(p<0.001),这些疾病大多没有、轻度或区域性神经增大[CIDP(64%)、GBS(95%)和 MMN(100%)]。在 CIDP 中,在疾病发病后 3 个月内接受治疗的患者比后来接受治疗的患者神经增大程度更小。超声可识别弥漫性神经增大的模式,可用于筛查疑似 CMT-1 的患者。脱髓鞘性多发性神经病中正常、轻度或区域性增大的神经提示获得性病因。CIDP 中的早期治疗可能会阻碍神经增大。